Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for JAMES BLOOM
+0.06 (0.08%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 71.48 - 73.69
52 week 38.49 - 73.69
Open 71.88
Vol / Avg. 1.24M/1.36M
Mkt cap 10.57B
P/E     -
Div/yield     -
EPS -0.29
Shares 146.23M
Beta 1.13
Inst. own 98%
Feb 10, 2015
Alkermes Plc at Biotechnology Industry Organization CEO & Investor Conference - 10:00AM EST - Add to calendar
Jan 13, 2015
Alkermes Plc at JPMorgan Healthcare Conference - Q&A Session
Jan 13, 2015
Alkermes Plc at JPMorgan Healthcare Conference
Dec 2, 2014
Alkermes Plc at NASDAQ OMX Investor Program - Webcast
Nov 11, 2014
Alkermes Plc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -24.97% -
Operating margin -20.46% -
EBITD margin - -
Return on average assets -8.67% -
Return on average equity -11.94% -
Employees 1,250 -
CDP Score - -


Connaught House 1 Burlington Road, Dublin 4
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures RISPERDAL CONSTA, VIVITROL and polymer for BYDUREON in its Wilmington, Ohio facility. The Company operates PERDAL CONSTA lines and one VIVITROL line at commercial scale. The Company manufactures AMPYRA/FAMPYRA, RAPAMUNE and other products in its Athlone, Ireland facility. It manufactures FOCALIN XR, RITALIN LA, AVINZA, VERAPAMIL and other products in its Gainesville, Georgia facility.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane Cooke President
Age: 51
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 56
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President, Corporate Communications
Age: 38
Bio & Compensation  - Reuters
Elliot W. Ehrich M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters